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S_nmary The present study reports on the frequency of MDM2 gene amplification and MDM2 protein
expression in a series of 100 breast carcinomas and its association with accumulation of the p53 protein. Of
the 100 cases, frozen samples for 82 cases were available for Southern blotting. Three of the 82 (4%)
demonstrated MDM2 gene amplification of up to 6-fold. Immunohistochemical analysis of the formalin-fixed,
paraffin-embedded tumours demonstrated that 7197 (7%) had nuclear expression for MDM2 in 10-50% of
the tumour cells (type 2 staining) and were denoted MDM2+. Two of the MDA2-amplified samples were
MDM2+ with one of the two tumours also displaying type 2 p53 nuclear staining. Finally at the protein level.
MDM2+ tumours were significantly associated with tumours having low levels of p53 staining (0-10% cells
positive) (P = 0.03). We conclude that MDM2 gene amplification occurs at a lower frequency in breast cancer
than in non-epithelial tumours. Alterations in MDM2 and p53 may represent alternative pathways in
tumorigenesis. but they are not mutually exclusive in all cases.
Keywords AfDM2; breast; p53; microwave; amplification
MDM2 is an evolutionarily conserved gene (Fakharzadeh et
al., 1991) which was originally identified as a highly amplified
gene present on double minutes in a spontaneously trans-
formed tumorigenic derivative of a Balb/c cell line called
3T3DM (Cahilly-Snyder et al., 1987). Subsequently, Oliner et
al. (1992) cloned the human MDM2 gene and localised it to
chromosome 12ql3-14. Analysis of the predicted amino acid
sequence of the MDM2 protein suggests that it may be a
DNA-binding protein or transcription factor (Fakharzadeh
et al., 1991; Oliner et al., 1992). In addition, it is also thought
to function as a regulator of p53 function. This stems from
evidence that the MDM2 protein forms oligomeric complexes
with the p53 protein in vivo and in vitro (Momand et al.,
1992; Oliner et al., 1992) and when experimentally over-
expressed inhibits the transactivating capability of p53
(Momand et al., 1992). This inhibition is thought to result
from the MDM2 protein binding directly to the acidic activa-
tion domain of p53, concealing it from the transcriptional
machinery (Oliner et al., 1993). Apart from its role as a p53
regulator, MDM2 also has oncogenic properties, as evident
from transfection studies in which MDM2 overexpression
was found to increase the tumorigenic potential of NIH3T3
and Rat2 cells (Fakharzadeh et al., 1991) and to overcome
wild-type p53 suppression of transformed cell growth (Finlay,
1993). Therefore, its role in tumorigenesis and its detectable
alteration in tumour samples is of clinical interest. At the
DNA level, a number of groups have examined MDM2
amplification in non-epithelial tumours. Of these, MDM2
amplification ranging from 4- to 70-fold has been reported in
14% (4/28) of osteogenic sarcomas (Ladanyi et al., 1993),
10% of primary brain tumours (15/157) (Reifenberger et al.,
1993) and up to 36% (17/47) of soft-tissue sarcomas (Oliner
et al., 1992; Leach et al., 1993a), with no apparent
amplification in Ewing tumours (Kovar et al., 1993) of
myelodysplastic syndrome (Preudhomme et al., 1993), ast-
rocytomas (Rubio et al., 1993) or leukaemia (Bueso-Ramos
et al., 1993). With regard to the epithelial malignancies, none
of the gastrointestinal tumours (Oliner et al., 1992), cervical
cancers (Kessis et al., 1993) or breast cell lines (Sheikh et al.,
1993) investigated showed evidence of aberrant MDM2 gene
copy number. Interestingly, at the mRNA level, two studies
found increased MDM2 expression with no apparent altera-
tion in MDM2 gene copy number (Bueso-Ramos et al., 1993;
Sheikh et al., 1993), suggesting that mechanisms other than
gene amplification may play a role in deregulating the expres-
sion of MDM2.
Therefore, the objectives of the present study were as
follows: firstly, to determine the frequency of MDM2
amplification in a series of breast carcinomas using Southern
blotting, which to our knowledge had not been assessed in
clinical breast tumour material; secondly, to investigate the
use ofmicrowave enhancement (Shi et al., 1991) for immuno-
histochemically evaluating the MDM2 protein in formalin-
fixed, paraffin-embedded material using the IF2 mouse
monoclonal antibody, which according to the originators
does not work on paraffin-embedded material (Leach et al..
1993a, thirdly, to correlate MDM2 amplification status with
MDM2 protein expression; and, finally, to determine the
association of altered MDM2 at the DNA and protein levels
with accumulation of p53.
MateriaL and mthod
Tumours
Of the 100 tumours analysed in the present study, 73 were
infiltrating ductal carcinomas (71 in females; two in male), 15
were infiltrating ductal with an in situ component (DCIS),
three were pure DCIS, seven were infiltrating lobular and
two were colloid carcinomas. Fresh breast samples were snap
frozen in liquid nitrogen and stored at -70°C before DNA
extraction. The corresponding paraffin-embedded tumours
were formalin fixed and processed according to routine histo-
logical techniques.
Southern blotting
Amplification of the MDM2 gene was studied by Southern
blotting analysis. Briefly, 10 g.g of high molecular weight
DNA from 82 frozen breast carcinomas were EcoRI digested,
electrophoretically separated in 0.8% agarose gels and alkali
blotted to Hybond N+ (Amersham) nylon membranes.
Following hybridisation with a [a-32PJdCLTP-labelled human
MDM2 cDNA probe (C14-2), the membranes were exposed
to intensifying screens for 2-10 days at -70°C. The blots
were subsequently reprobed with the pDCCl.65 probe, which
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contains nucleotides 591-2250 of the deleted in colorectal
cancer (DCC) gene (Fearon et al., 1990). This probe, which
detects fragments of similar size as MDM2-probed EcoRI
DNA, was used as a control probe similar to a previous
study (Oliner et al., 1992). Hybridisation conditions were
similar to those previously used (Ohner et al., 1992). Tumour
samples were considered amplified following (a) companson
of amplified signals to germline placental controL (b) evalua-
tion of consistent well loading by examination of ethidium
bromide-stained agarose gels before Southern transfer and by
reprobing with the control gene probe (pDCC 1.65) and,
finally, (c) serial dilutional analysis ofamplified samples. The
probes were kindly donated by Dr J Oliner and Dr B Vogels-
tein (Johns Hopkins University, Baltimore, MD, USA).
Imnmohistochemistry
The MDM2 and p53 proteins were immunohistochemically
assessd on air-dried 5pm formalin-fixed, paraffin-embedded
sections using the commercially available IF2 (Oncogene
Science) and NCL-p53 D07 (Novacastra Laboratories)
mouse monoclonal antibodies respectively. In the case of
MDM2, immunoreactivity was not detectable on paraffin-
embedded sections using IF2 and standard immunohisto-
chemical procedures. Microwaving of the sections before
application of the antibody proved successful. Briefly, the
sections were placed in a microwaveable trough, submerged
in 10 mm citrate buffer (pH 6.01), wrapped in vented
clingfllm and incubated for two 5 min periods at maximum
power in a domestic microwave (Beling model MW 820T-
800W). Following microwaving, the sections were allowed to
come to room temperature in the buffer and rinsed in dis-
tilled water. The MDM2 (IF2) antibody was applied to the
sections at a 1:75 dilution for IO min at room
temperature.
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The p53 antibody (DO7) was used at a 1:50 dilution for
I h at room temperature. Comparative studies of frozen sec-
tions using this protocol showed good correlation and, there-
fore, microwave enhancement was not investigated for this
antibody. There have been reports, however, that such treat-
ment may enhance staining with this antibody (Gown et al.,
1993). Immunoreactivity for both p53 and MDM2 was dem-
onstrated using the universal labelled streptavidin-biotin
(LSAB), horseradish peroxidase (HRP) kit (Dako) according
to the manufacturer's instructions. The sections were
counterstained in 0.3% methyl green and scored semiquanti-
tatively following scanning of the entire tumour field.
Nuclear immunoreactivity for MDM2 and p53 was scored as
negative (0%), type I (<10% nuclei positive), type 2 (10-
50% nuclei positive) and type 3 (>50% nuclei positive). The
significane of MDM2 nuclear staining with other cinico-
pathologial features including accumulated p53 status was
assessed using the X2-test.
Redsis
Amplification
In the present study, frozen tissue was available for Southern
blotting analysis in 82/100 of cases. Of these, MDM2
amplification was present in 4% (3/82) (Figure 1, blots la
and 2a), and these were histologically classified as infiltrating
ductal. The corresponding blots showing reprobing with the
control probe pDCCl.65 are also shown (Figure 1, blots lb
and 2b respectively). Sample 10 (Figure 1, blot la), demon-
strated the highest gene copy number based on serial dilu-
tional analysis (4- to 6-fold) and was from a patient whose
mother died from breast cancer at the age of 48 and whose
brother died at 25 from liver cancer with an unknown
b
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Figwe 1 Souther blot analysis of MDM2 gene amplfication in EcoRI restrit breast DNA samples hybridised with a human
MDM2 cDNA fragment (C-14-2) (blots la and 2a) with corresponding reprobing of the blots with pDCCl.65 (blots lb and 2b
respectively). The case numbers are given on the tops of each lane. Tumour DNA samples 10, 16 and 19 show amplifcation for
MDM2 (see arrows). Germine placental controls are indicated (P) and appromate DNA fragment sizes are shown on the left in
kilobases (kb).Ateration of MDM2 in breast cancer
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Figure 2 Photomicrographs of (a) and MDM2+ infiltrating duc-
tal carcinoma showing heterogeneity of nuclear staining using
microwave enhancement and incubation with the IF2 mouse
monoclonal antibody and (b) immunoreactivity for p53 demon-
strating widespread nuclear staining in an infiltrating ductal car-
cinoma using the D07 mouse monoclonal antibody.
primary. The remaining two MDM2-amplified samples
(tumours 16 and 19) (Figure 1, blot 2a) had a 2- 4-fold
amplification based on serial dilutional analysis.
Expression
Immunoreactivity for the MDM2 and p53 gene products was
predominantly located in the nucleus (Figure 2a and b
respectively), with some weak cytoplasmic staining. Of the 97
samples assayed, 7% (7/97) had type 2 MDM2 nuclear stain-
ing [10-50% of tumour nuclei positive (MDM2+) Table I].
With the exception of one case of ductal carcinoma in situ
(DCIS) (histologically typed as cribiform), all the MDM2+
cases were infiltrating ductal carcinomas. None of the
tumours had type 3 staining (>50% nuclei positive). Type 1
and negative staining frequencies are detailed in Table I, as
are the frequencies for p53 nuclear accumulation.
Comparing MDM2 amplification with MDM2 and p53
nuclear protein expression, 2/3 MDM2-amplified samples
were MDM2+ (type 2 staining) and one was negative (Table
II). Of the three amplified samples, only one had gross
accumulation of p53 (type 2 staining; sample 16). The two
remaining amplified tumours consisted of one tumour nega-
tive for p53 (sample 19) and one with type 1 staining (<10%
nuclear positivity; sample 10) (Table II). Finally, 95 cases
were assayed for both p53 and MDM2 protein expression
using immunohistochemistry. Chi-square analysis indicated
that MDM2+ status was significantly associated (P = 0.03)
with low levels of p53 (negative and type 1 staining; Table
III), with 6/7 MDM2+ tumours having this p53 profile. Of
note is the fact that 5/7 of these MDM2+ tumours had no
underlying gene amplification (Table II). With regard to the
other clinicopathological variables looked at, MDM2+ status
Table I Frequency of MDM2 and p53 nuclear staining
Type 3 Type 2 Type I Negative
Antigen (>50%)' (10-50%) (<10%) (-)
MDM (n=97) - 7 (7%) 14 (15%) 76 (78%)
p53 (n=97) 28 (29%) 10 (10%) 19 (20%) 40 (41%)
aPercentage of tumour nuclei with immunoreactivity.
Table II Association of altered MDM2 with accumulated p53
status
MDM2 copy MDM2 Accumulated pS3
Samples number expression' status"
Amplified
10 4-6 + Type 1
16 2-4 + Type 2
19 2-4 Negative Negative
Non-amplif ied
15 - + Type 1
30 - + Negative
45 - + Negative
47 - + Type 1
60 - + Type I
a+ indicates type 2 MDM2 staining (10-50% of tumour nuclei
positive). bp53 nuclear accumulation as described in the Materials
and methods section.
Table III Association of MDM2 protein status with nuclear p53
staining
MDM2 nuclear expressionb
Total no. Type 2 Type I
p53 nuclear accumulationa of cases (10-50%)(<10%) Negative
Type 2 and 3 37 1 2 34
Type 1 and negative 58 6 12 40
Total 95 7 14 74
ap53 nuclear accumulation as described in the Materials and
methods section. bMDM2 nuclear expression as described in
Materials and methods section. cSignificance level P = 0.03 using x2
analysis.
was not associated with age, tumour grade, lymph node
status or tumour size (data not shown).
Discussion
In the present study, we investigated the frequency of MDM2
alteration at both the DNA and protein levels in an epithelial
tumour, namely breast cancer, and correlated the findings
with immunohistochemical accumulated p53 status. Our
investigation was prompted by the fact that other studies on
epithelial tumours or cell lines (Oliner et al., 1992; Kessis et
al., 1993; Sheikh et al., 1993) found no MDM2 gene
amplification. In the present study, altered MDM2 gene copy
number was evident in 4% of breast carcinomas. This fre-
quency is lower than that reported in the literature for non-
epithelial malignancies (Oliner et al., 1992; Ladanyi et al.,
1993; Reifenberger et al., 1993; Leach et al., 1993a), and is
one of the first reports of MDM2 amplification in epithelial
tumours. The clinical significance of such amplification is yet
to be clarified. In the study of Ladanyi et al. (1993), in-
creased MDM2 gene copy number was detected more fre-
quently in metastatic or recurrent rather than in primary
high-grade osteosarcomas (P = 0.02) suggesting that such
alteration may be associated with tumour progression. The
finding of a 2-fold increase in MDM2 copy number and
RNA expression in a recurrent glioblastoma sample com-
pared with the primary lesion supports this view (Reifen-
berger et al., 1993).
In the present study, the highest degree of amplification
was present in tumour DNA from a woman who appeared to
have a family history of cancer, suggesting that investigations
of MDM2 alterations in cancer families may be of interest.
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This stems from reports of a lack of p53 mutations in exons
5-9 of familial breast cancer patients (Prosser et al., 1991;
Warren et al., 1992), suggesting p53 mutations may not
contribute to hereditary breast cancer. Is it possible that
MDM2 could play a role in these cases? It is hard to con-
ceive however, how gene amplification could be inherited,
and it may be that some other mechanism could predispose
to an amplification event. One possibility is that an inherited
mutation in a gene responsible for the fidelity of DNA
replication, such as MSH2 (Leach et al., 1993b), could result
in genomic instability leading to gene amplification.
Microwave-based antigenic unmasking has recently been
evaluated by our group (Kelleher et al., 1994) and others,
and is a recommended technique for use in paraffin material
for detecting a wide range ofantigens (Shi et al., 1991; Gown
et al., 1993). The frequency of 7% positive immunostaining
for the MDM2 protein is slightly higher than the altered
frequency we report at the DNA level and may suggest that
mechanisms other than gene amplification can lead to aber-
rant MDM2 expression, for example oestrogen may modu-
late MDM2 mRNA expression (Shiekh et al., 1993).
The fact that one of our amplified samples had no appar-
ent alteration in MDM2 protein expression suggests that in a
subset of tumours the amplification event could be driven by
a different gene within this chromosomal region. Possible
candidate genes are CDK4 or gli, which have been reported
to be co-amplified with MDM2 in an osteosarcoma cell line
(Khatib et al., 1993). The 12ql3-14 amplicon may therefore
represent a similar situation to that found with the llql3
regional locus in breast carcinomas, in which int-2, although
not expressed, is frequently co-amplified with hst-1 and bel-l
(cyclinD/PRAD1), with the latter reported to have elevated
transcription accompanied by its amplification (Yoshida et
al., 1993).
Looking at MDM2 gene amplification in association with
accumulated p53 status, 1/3 amplified MDM2+ tumours
demonstrated type 2 p53 nuclear staining (10-50% of
tumour nuclei positive). This is similar to a previous study
(Reifenberger et al., 1993) in which two MDM2-amplified
samples displayed significantly increased levels of p53
mRNA, with one case showing concomitant p53 nuclear
expression in the majority of the tumour nuclei as determined
using the D07 antibody. The significance of this accumula-
tion in the present study is difficult to interpret without
sequence analysis. Firstly, accumulation of p53 in the
majority of cases has been shown to be synonymous with the
presence of underlying p53 mutations (Singh el al., 1993).
These mutations, however, have not been found in any of the
MDM2-amplified samples reported in the literature (Oliner et
al., 1992; Reifenberger et al., 1993; Leach et al., 1993a),
suggesting that MDM2 amplification and p53 exonic muta-
tions may be mutually exclusive. Secondly, based on the
study of Barnes et al. (1992) reporting on the accumulation
of non-mutated, wild type p53 in a familial case, we used the
D07 antibody in our study as it detects both the wild-type
and mutant p53 forms. Therefore, the accumulation ofp53 in
this amplified tumour could be of either phenotype and may
be due to sequestering by MDM2. Of course, other
mechanisms could lead to p53 accumulation resulting from
intronic mutations, altered splice patterns, increased protein
stability or sequestering by other host proteins. The proposed
p53- MDM2 autoregulatory feedback loop (Wu et al., 1993)
and the identification of multiple MDM2 proteins and possi-
ble MDM2-p53 protein complexes (Olson et al., 1993) fur-
ther underlines the complexity of maintaining p53 equilib-
rium.
In conclusion, our study reports on a frequency of 4% for
amplification of the MDM2 gene in human breast cancer and
expression of the MDM2 gene product (10-50% nuclei
positive) in 7% of samples, and is one of the first reports of
such an alteration in epithelial tumours. Based on this fre-
quency, it is unlikely that altered MDM2 will have significant
clinical value, but this remains to be determined. The fact
that 6/7 MDM2-positive protein samples were p53 negative
(P = 0.03) indicates that alterations in MDM2 and p53 may
represent alternative pathways in tumorigenesis. Finally, the
role of MDM2 alteration in familial/inherited dispositions
may be warranted.
Abbreviations
MDM2, murine double minute 2; cDNA, complementary DNA,
DCIS, ductal carcinoma in situ; ER, oestrogen receptor.
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